Random Urine, 2,3-Dinor 11 Beta-Prostaglandin F2 Alpha
Test Catalog Information
| Test Catalog Synonyms | |
| EPIC Synonyms |
2,3-Dinor-11b-Prostaglandin F2a, RU 23BPR |
| Cerner Primary Mnemonic | 2,3-Dinor-11b-Prostaglandin F2a, RU |
| EPIC Display Name | Random Urine, 2,3-Dinor 11 Beta-Prostaglandin F2 Alpha |
| Allscripts (AEHR) Order Name | 2,3-dinor-11b-Prostaglandin F2a, Random Urine |
| Sunrise Clinical Manager (SCM) Order Name | 2,3-dinor-11b-Prostaglandin F2a, Random Ur |
| EPIC Inpatient Orderable | Yes |
| EPIC Outpatient Orderable | Yes |
| Cerner Results |
Creatinine Random Urine 2,3-dinor-11b-Prostaglandin F2a, RU |
| Clinical Info |
Screening for mast cell activation disorders including systemic mastocytosis using random urine specimens 2,3-Dinor-11beta-prostaglandin F2 alpha (2,3 BPG) is the most abundant metabolic product of prostaglandins released by activated mast cells. Systemic mastocytosis (SM) is a disease in which clonally derived mast cells accumulate in peripheral tissues. Degranulation of these mast cells releases large amounts of histamines, prostaglandins, leukotrienes, and tryptase. World Health Organization diagnostic criteria for SM require the presence of elevated mast cell counts on a bone marrow biopsy and 1 of the following minor criteria: abnormal mast cell morphology, KIT Asp816Val variant, CD25-positive mast cells, or serum tryptase greater than 20 ng/mL. Alternatively, SM diagnosis can be made with the presence of 3 minor criteria in the absence of abnormal bone marrow studies. Measurement of mast cell mediators in blood or urine is less invasive and is advised for the initial evaluation of suspected cases. Elevated levels of serum tryptase, urinary N-methylhistamine, 2,3 BPG, or leukotriene E4 are consistent with the diagnosis of systemic mast cell disease. |
| Specimen Type |
Urine |
| Container |
Urine Cup |
| Collection Instructions |
Container/Tube: Urine Container Specimen: 5 mL Random Urine (4 mL min) Transport Temperature: Refrigerated Stability: 8 Hours Room Temperature 14 Days Refrigerated 30 Days Frozen |
| Transport Instructions |
Refrigerated |
| Specimen Stability |
8 Hours Room Temperature 14 Days Refrigerated 30 Days Frozen |
| Methodology |
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Creatinine: Enzymatic Colorimetric Assay |
| Days Performed |
TAT: 3-7 Days |
| Performing Laboratory |
Mayo Medical Laboratories |
| CPT |
84150 82570 LOINC Code: 97658-9 |
| PDM |
2159269, 23BPR |
Desired Epic Build Random Urine, 2,3-Dinor 11 Beta-Prostaglandin F2 Alpha
| Cerner Primary Mnemonic: | 2,3-Dinor-11b-Prostaglandin F2a, RU | |||||||||
| PDM | 2159269 | |||||||||
| Informatics - Workgroup | Endocrine | |||||||||
| Synonyms * | 2,3-Dinor-11b-Prostaglandin F2a, RU 23BPR | |||||||||
| Display Name * | Random Urine, 2,3-Dinor 11 Beta-Prostaglandin F2 Alpha | |||||||||
| Order Entry Specimen Sources * | ||||||||||
| Order Entry Specimen Types | ||||||||||
| Specimen Navigator Specimen Types | ||||||||||
| Specimen Navigator Specimen Sources | ||||||||||
| Specimen Navigator Short Name | ||||||||||
| Ordering info (EPIC SmartText) | Screening for mast cell activation disorders including systemic mastocytosis using random urine specimens 2,3-Dinor-11beta-prostaglandin F2 alpha (2,3 BPG) is the most abundant metabolic product of prostaglandins released by activated mast cells. Systemic mastocytosis (SM) is a disease in which clonally derived mast cells accumulate in peripheral tissues. Degranulation of these mast cells releases large amounts of histamines, prostaglandins, leukotrienes, and tryptase. World Health Organization diagnostic criteria for SM require the presence of elevated mast cell counts on a bone marrow biopsy and 1 of the following minor criteria: abnormal mast cell morphology, KIT Asp816Val variant, CD25-positive mast cells, or serum tryptase greater than 20 ng/mL. Alternatively, SM diagnosis can be made with the presence of 3 minor criteria in the absence of abnormal bone marrow studies. Measurement of mast cell mediators in blood or urine is less invasive and is advised for the initial evaluation of suspected cases. Elevated levels of serum tryptase, urinary N-methylhistamine, 2,3 BPG, or leukotriene E4 are consistent with the diagnosis of systemic mast cell disease. | |||||||||
| IP Orderable | Yes | |||||||||
| OP Orderable | Yes | |||||||||
|
AOEs * | ||||||||||
| AP AOEs | ||||||||||
| Special History | No | |||||||||
| Build Comments | ||||||||||
| Filter * | ||||||||||
| Procedure Category Change | ||||||||||
Cerner Results
| ||||||||||
Actual Epic build
| Procedure Id | |||||||||||||||||||
| Pdm | |||||||||||||||||||
| Order Display Name | |||||||||||||||||||
| Procedure Name | |||||||||||||||||||
| Procedure Master Number | |||||||||||||||||||
| Short Procedure Name | |||||||||||||||||||
| Category Code | |||||||||||||||||||
| Category Code Record Name | |||||||||||||||||||
| Synonyms | |||||||||||||||||||
| Clinically Active | |||||||||||||||||||
| Orderable | |||||||||||||||||||
| Performable | |||||||||||||||||||
| Filter Genomics | |||||||||||||||||||
| Reference Link Url | |||||||||||||||||||
| Ordering Instructions | |||||||||||||||||||
| Default Specimen Type | |||||||||||||||||||
| Specimen Type Pick List | |||||||||||||||||||
| Specimen Type List | |||||||||||||||||||
| Op Specimen Type List | |||||||||||||||||||
| Specimen Source Pick List | |||||||||||||||||||
| Specimen Source Default - Male | |||||||||||||||||||
| Specimen Source Default - Female | |||||||||||||||||||
| Specimen Source List | |||||||||||||||||||
| Op Specimen Source List | |||||||||||||||||||
| Ip Lab Test Components For Report | |||||||||||||||||||
| Op Lab Test Components For Report | |||||||||||||||||||
| Order Questions | |||||||||||||||||||
| Order Questions Record Name | |||||||||||||||||||
| Inpatient Order Questions | |||||||||||||||||||
| Inpatient Order Questions Record Name | |||||||||||||||||||
| Order Specific Question Override | |||||||||||||||||||
| Inpatient Question Override | |||||||||||||||||||
| Location Restrict List Ip | |||||||||||||||||||
| Location Restrict List Ip Record Name | |||||||||||||||||||
| Location Restrict List Include Ip | |||||||||||||||||||
| Location Restrict List Op | |||||||||||||||||||
| Location Restrict List Op Record Name | |||||||||||||||||||
| Location Restrict List Includes Op | |||||||||||||||||||
| Edp Amb Order Specific Questions Record Name | |||||||||||||||||||
| Edp Ip Order Specific Questions Record Name | |||||||||||||||||||
| Edp Ip Specimen Source | |||||||||||||||||||
| Edp Op Specimen Source | |||||||||||||||||||
| Edp Ip Specimen Type | |||||||||||||||||||
| Edp Op Specimen Type | |||||||||||||||||||
| Derived Edp Ip Buttons S | |||||||||||||||||||
| Derived Edp Ip Buttons T | |||||||||||||||||||
| Derived Edp Op Buttons S | |||||||||||||||||||
| Derived Edp Op Buttons T | |||||||||||||||||||
| Ip Orderable | |||||||||||||||||||
| Op Orderable | |||||||||||||||||||
| EPIC OP AOEs | |||||||||||||||||||
| EPIC IP AOEs | |||||||||||||||||||
EPIC Components (results)
| |||||||||||||||||||